Research programme: amyotrophic lateral sclerosis gene therapy - Ceregene/Salk InstituteAlternative Names: AAV-IGF-1; ALS gene therapy - Ceregene/Salk Institute; CERE-135; IGF-1 gene therapy
Latest Information Update: 28 Oct 2013
At a glance
- Originator Salk Institute
- Developer Ceregene
- Class Gene therapies
- Mechanism of Action Gene transference; Insulin-like growth factor I stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Amyotrophic lateral sclerosis